卖剩余安眠药被判贩毒?“不浪费”应有更好的办法

Core Viewpoint - The case of a woman selling five boxes of the controlled substance "Sino-Sleep" online has been sent back for retrial due to unclear facts in the original judgment, raising questions about the intent behind her actions and the regulation of controlled substances in China [1] Group 1: Case Details - The woman, identified as Ma, sold five boxes (35 tablets) of Sino-Sleep online for a profit of 300 yuan, and was later charged with drug trafficking [1] - Initially sentenced to seven months in prison with a one-year probation and a fine of 2,000 yuan, the case has garnered public attention due to the perception of Sino-Sleep as a common sleeping aid rather than a controlled substance [1] - The focus of the controversy lies in whether Ma had the intent to sell drugs, which is crucial for establishing the criminal charge [1] Group 2: Regulatory Issues - Sino-Sleep is classified as a Category II controlled substance in China, which poses addiction risks if misused and must be purchased with a prescription [2] - There are existing issues with the over-prescription of such drugs, as evidenced by past cases where individuals exploited gaps in hospital prescription records to obtain excessive quantities [2] - The current regulatory framework for Category II controlled substances is weak, leading to potential legal risks for patients who may not be aware of the laws surrounding the disposal of leftover medications [2] Group 3: Recommendations for Improvement - There is a need for a structured mechanism for the return and disposal of Category II controlled substances, similar to existing regulations for Category I substances [3] - Encouraging patients to return unused medications through incentive programs could enhance public awareness of the risks associated with these drugs [3] - The case highlights the necessity for improved regulations on the prescription and distribution of controlled substances to prevent misuse while ensuring patient safety [3]